ReviewAdvances in experimental medicine and biology2021
The Good, the Bad and the Ugly of Testicular Immune Regulation: A Delicate Balance Between Immune Function and Immune Privilege.
Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Resilience and residuals beyond containment - The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study.New microbes and new infections · 2026Article
- Article
- Viral persistence in long COVID: Research advances and treatment strategies.Infectious diseases & immunity · 2025Review
- Review
- T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets.British journal of cancer · 2024Article
- Morphology of the immune cells in the wall of the human uterine tube and their possible impact on reproduction-uterine tube as a possible immune privileged organ.Frontiers in cell and developmental biology · 2024Review
- The Sertoli Cell Complement Signature: A Suspected Mechanism in Xenograft Survival.International journal of molecular sciences · 2023Article
- Transmigration of macrophages through primary adult rat Sertoli cells.Tissue barriers · 2023Article
- Testicular pathological alterations associated with SARS-CoV-2 infection.Frontiers in reproductive health · 2023Review
- Tissue-resident immunity in the female and male reproductive tract.Seminars in immunopathology · 2022Review
- Why does viral RNA sometimes persist after recovery from acute infections?PLoS biology · 2022Article
- Sertoli Cell Immune Regulation: A Double-Edged Sword.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The testis is one of several immune privilege sites. These sites are necessary to decrease inflammation and immune responses that could be damaging to the host. For example, inflammation in the brain, eye or placenta could result in loss of cognitive function, vision or rejection of the semi-allogeneic fetus, respectively. In the testis, immune privilege is "good" as it is necessary for protection of the developing auto-immunogenic germ cells. However, there is also a downside or "bad" part of immune privilege, where pathogens and cancers can take advantage of this privilege and persist in the testis as a sanctuary site. Even worse, the "ugly" of privilege is how re-emerging viruses, such as Ebola and Zika viruses, can establish persistence in the testes and be sexually transmitted even months after they have been cleared from the bloodstream. In this review, we will discuss the delicate balance within the testis that provides immune privilege to protect the germ cells while still allowing for immune function to fight off pathogens and tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.